ViennaLab Diagnostics GmbH

Test for genetic markers that influence highly active antiretroviral therapy (HAART) in HIV-positive patients.

Highly active retroviral therapy (HAART) is a very effective treatment for HIV-positive patients. Allelic variants of certain proteins have been associated with successful HAART. The PGX-HIV StripAssay® identifies variants in genes known to be relevant for effective HAART.




  • HAART has brought about substantial improvements to HIV-positive patients and has led to a significant reduction in AIDS-related mortality in countries with access to the treatment.
  • Allelic variants of the multidrug transporter P-glycoprotein 1 (MDR1), cytochrome P450 isozyme 2D6 (CYP2D6), and the C-C chemokine receptor 5 (CCR5) are known to be associated with the best possible outcome of HAART.
  • Identification of relevant genetic variations supports better guidance of HIV therapy.
  • The PGX-HIV StripAssay® identifies genetic variants, which influence the efficacy of HAART, and can help to adjust therapy to individual needs.


ProductReg. Stat.REFUnit SizeIFUBrochure
PGX-HIV StripAssay® CE/IVD4-71020 tests



We use Matomo to analyze the access to our website. We pass on information about your use of our website to our partners for analysis. Our partners may combine this information with other data that you have provided to them or that they have collected as part of your use of the services. I agree.

Deny Allow